Catalyst Biosciences Valuation

Catalyst Biosciences Investor Information

About 28.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.53. Some equities with similar Price to Book (P/B) outperform the market in the long run. Catalyst Biosciences has Price/Earnings To Growth (PEG) ratio of 0.02. The entity recorded a loss per share of 1.5. The firm last dividend was issued on the 13th of January 2023. Catalyst Biosciences had 1:15 split on the 13th of February 2017. Based on the key indicators related to Catalyst Biosciences' liquidity, profitability, solvency, and operating efficiency, Catalyst Biosciences is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.

Catalyst Biosciences Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Catalyst Biosciences has an asset utilization ratio of 2.79 percent. This suggests that the Company is making $0.0279 for each dollar of assets. An increasing asset utilization means that Catalyst Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.

Catalyst Biosciences Ownership Allocation

Catalyst Biosciences holds a total of 37.97 Million outstanding shares. Catalyst Biosciences retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Catalyst Biosciences Profitability Analysis

The company reported the previous year's revenue of 794 K. Net Loss for the year was (8.24 M) with loss before overhead, payroll, taxes, and interest of (64.91 M).

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

If you are still planning to invest in Catalyst Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catalyst Biosciences' history and understand the potential risks before investing.